You May Also Like

How Novo Nordisk partners with academia, biotech companies and beyond
oliver.stula@baselarea.swiss26.09.2025

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2
oliver.stula@baselarea.swiss24.09.2025

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer
oliver.stula@baselarea.swiss12.08.2025